Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern

Pollet J.; Strych U.; Chen W.-H.Versteeg L.Keegan B.Zhan B.Wei J.Liu Z.Lee J.Kundu R.Adhikari R.Poveda C.Jose Villar M.Rani Thimmiraju S.Lopez B.Gillespie P.M.Ronca S.Kimata J.T.Reers M.Paradkar V.Hotez P.J.Elena Bottazzi M.

首页> 外文期刊>Vaccine >Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern

【24h】

Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern

机译：Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相关主题

摘要

© 2022 The AuthorsWe conducted preclinical studies in mice using a yeast-produced SARS-CoV-2 RBD subunit vaccine candidate formulated with aluminum hydroxide (alum) and CpG deoxynucleotides. This formulation is equivalent to the CorbevaxTM vaccine that recently received emergency use authorization by the Drugs Controller General of India. We compared the immune response of mice vaccinated with RBD/alum to mice vaccinated with RBD/alum + CpG. We also evaluated mice immunized with RBD/alum + CpG and boosted with RBD/alum. Mice were immunized twice intramuscularly at a 21-day interval. Compared to two doses of the /alum formulation, the RBD/alum + CpG vaccine induced a stronger and more balanced Th1/Th2 cellular immune response, with high levels of neutralizing antibodies against the original Wuhan isolate of SARS-CoV-2 as well as the B.1.1.7 (Alpha), B.1.351 (Beta), B.1.617.2 and (Delta) variants. Neutralizing antibody titers against the B.1.1.529 (BA.1, Omicron) variant exceeded those in human convalescent plasma after Wuhan infection but were lower than against the other variants. Interestingly, the second dose did not benefit from the addition of CpG, possibly allowing dose-sparing of the adjuvant in the future. The data reported here reinforces that the RBD/alum + CpG vaccine formulation is suitable for inducing broadly neutralizing antibodies against SARS-CoV-2, including variants of concern.

著录项

来源
《Vaccine》 |2022年第26期|3655-3663|共9页
作者
Pollet J.; Strych U.; Chen W.-H.Versteeg L.Keegan B.Zhan B.Wei J.Liu Z.Lee J.Kundu R.Adhikari R.Poveda C.Jose Villar M.Rani Thimmiraju S.Lopez B.Gillespie P.M.Ronca S.Kimata J.T.Reers M.Paradkar V.Hotez P.J.Elena Bottazzi M.;
展开▼
作者单位

Texas Children's Hospital Center for Vaccine Development;

Department of Pediatrics and Molecular Virology & Microbiology National School of Tropical Medicine Baylor College of Medicine;

Department of Molecular Virology and Microbiology Baylor College of MedicineBiological E Limited;

展开▼
收录信息
原文格式 PDF
正文语种英语
中图分类医学免疫学;
关键词
Corbevax; COVID-19; Subunit vaccine; TLR9 adjuvant; Virus neutralization;

Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern

摘要

著录项

相关主题

期刊订阅